Show simple item record

dc.contributor.authorRodriguez-Serrano, María
dc.contributor.authorRueda, Joaquín
dc.contributor.authorBuendía, Francisco
dc.contributor.authorMonto, Fermi
dc.contributor.authorAguero, Jaume 
dc.contributor.authorOsa, Ana
dc.contributor.authorCano, Oscar
dc.contributor.authorMartínez-Dolz, Luis
dc.contributor.authorD'Ocon, Pilar
dc.date.accessioned2019-03-15T13:04:07Z
dc.date.available2019-03-15T13:04:07Z
dc.date.issued2019
dc.identifier.citationFront Pharmacol. 2019; 10:93es_ES
dc.identifier.issn1663-9812es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7343
dc.description.abstractPulmonary regurgitation (PR) is a frequent complication after repair of congenital heart disease. Three different GRK isoforms (GRK2, GRK5, and GRK3) and two β-adrenoceptors (β1-AR and β2-AR) are present in peripheral blood mononuclear cells (PBMC) and their expression changes as a consequence of the hemodynamic and neurohumoral alterations that occur in some cardiovascular diseases. Therefore, they could be useful as biomarkers in PR. A prospective study was conducted to describe the expression (TaqMan Gene Expression Assays) of β-ARs and GRKs in PBMC isolated (Ficoll® gradient) from patients with severe PR before and after pulmonary valve replacement and establish if this expression correlates to clinical status. 23 patients with severe PR were included and compared with 22 healthy volunteers (controls). PR patients before the PVR had a significantly lower expression of β2-AR (513.8 ± 261.2 mRNA copies) vs. controls (812.5 ± 497.2 mRNA copies), so as GRK2 expression (503.4 ± 364.9 copies vs. 858.1 ± 380.3 mRNA copies). The expression of β2-AR and GRK2 significantly decreases in symptomatic and asymptomatic patients, as well as in patients under treatment with beta-blockers and non-treated patients. The expression of β2-AR and GRK2 in PR patients recovers the normal values after pulmonary valve replacement (754,8 ± 77,1 and 897,8 ± 87,4 copies, respectively). Therefore, changes in the expression of β2-AR and GRK2 in PBMC of PR patients, could be considered as potential biomarkers to determine clinical decisions.es_ES
dc.description.sponsorshipThis study has been supported by a research grant from the Ministry of Economy and Competitiveness of Spain (SAF2013-45362-R).es_ES
dc.language.isoenges_ES
dc.publisherFrontiers in Biosciencees_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectGRK2es_ES
dc.subjectcongenital heart diseasees_ES
dc.subjectpulmonary regurgitationes_ES
dc.subjectpulmonary valve replacementes_ES
dc.subjectright ventriclees_ES
dc.subjectβ2-adrenoceptores_ES
dc.titleβ2-Adrenoceptors and GRK2 as Potential Biomarkers in Patients With Chronic Pulmonary Regurgitationes_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID30837872es_ES
dc.format.volume10es_ES
dc.format.page93es_ES
dc.identifier.doi10.3389/fphar.2019.00093es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fphar.2019.00093es_ES
dc.identifier.journalFrontiers in pharmacologyes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.repisalud.institucionCNICes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2013-45362-Res_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional